Purpuric drug eruption and alopecia induced by erlotinib.
We herein report a case of diffuse alopecia with pustules on the scalp and purpuric lesions on the lower legs in a Japanese man after treatment with erlotinib. This is a unique case in which rare skin eruptions simultaneously occurred. We discuss herein a combination of skin eruptions as an adverse reaction of epidermal growth factor-receptor (EGF-R) tyrosine kinase inhibitor. It is indispensable to be aware of rare skin reactions when applying molecular targeting therapies.
Taeko
T
Nakamura-Wakatsuki
Toshiyuki
T
Yamamoto
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000505:Alopecia / Q000139:chemically induced*; D020405:Dermis / Q000473:pathology; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D000069347:Erlotinib Hydrochloride; D006801:Humans; D007866:Leg; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011799:Quinazolines / Q000009:adverse effects*
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride